Histone demethylase enzymes KDM5A and KDM5B modulate immune response by suppressing transcription of endogenous retroviral elements
preprint
OA: closed
CC-BY-NC-ND-4.0
Abstract
Epigenetic factors, including lysine-specific demethylases such as the KDM5 paralogs KDM5A and KDM5B have been implicated in cancer and the regulation of immune responses. Here, we performed a comprehensive multiomic study in cells lacking KDM5A or KDM5B to map changes in transcriptional regulation and chromatin organization. RNA-seq analysis revealed a significant decrease in the expression of Krüppel-associated box containing zinc finger ( KRAB-ZNF ) genes in KDM5A or KDM5B knockout cell lines, which was accompanied by changes ATAC-seq and H3K4me3 ChIP-seq. Pharmacological inhibition of KDM5A and KDM5B catalytic activity with a pan-KDM5 inhibitor, CPI-455, did not significantly change KRAB-ZNF expression, raising the possibility that regulation of KRAB-ZNF expression does not require KDM5A and KDM5B demethylase activity. KRAB-ZNF are recognized suppressors of the transcription of endogenous retroviruses (ERVs) and HAP1 cells with KDM5A or KDM5B gene inactivation showed elevated ERV expression, increased dsRNA levels and elevated levels of immune response genes. Acute degradation of KDM5A using a dTAG system in HAP1 cells led to increased ERV expression, demonstrating that de-repression of ERV genes occurs rapidly after loss of KDM5A. Co-immunoprecipitation of KDM5A revealed an interaction with the Nucleosome Remodeling and Deacetylase (NuRD) complex suggesting that KDM5A and NuRD may act together to regulate the expression of ERVs through KRAB-ZNFs. These findings reveal roles of KDM5A and KDM5B in modulating ERV expression and underscore the therapeutic potential of using degraders of KDM5A and KDM5B to modulate tumor immune responses. Author Summary The histone demethylases KDM5A and KDM5B are transcriptional repressors that play an important role in cancer and immune response, making them attractive drug targets. Unfortunately, small molecule inhibitors, including CPI-455, that block KDM5A and KDM5B enzymatic activity, have shown only limited effectiveness at suppressing cancer cell viability as single agents in vitro. In this study we undertook a multi-omics approach to map transcriptional and chromatin changes in KDM5A and KDM5B deficient cells compared to those treated with CPI-455. The datasets revealed that KDM5A and KDM5B modulate the expression of KRAB-ZNF genes and that loss of either gene was associated with increased expression of ERV genes and upregulation of immune response markers. Surprisingly, pharmacological inhibition of these enzymes did not phenocopy genetic ablation. In contrast, acute degradation of KDM5A using a dTAG system caused an increase in ERV expression, providing evidence that this immune modulation is independent of demethylase activity. Together with the limited success of small molecule inhibitors, our data provide strong rationale for the development of KDM5A and KDM5B degraders to modulate tumor immune responses.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.
References (52)
- doi:10.1038/s41573-020-0077-5 via crossref
- doi:10.1016/j.trecan.2020.02.003 via crossref
- doi:10.1186/s13148-021-01100-x via crossref
- doi:10.1016/j.it.2020.06.002 via crossref
- doi:10.3389/fimmu.2022.809761 via crossref
- doi:10.1038/nrd4154 via crossref
- doi:10.1016/j.ccell.2018.10.014 via crossref
- doi:10.1371/journal.pbio.2006134 via crossref
- doi:10.1158/2326-6066.cir-22-0088 via crossref
- doi:10.1038/s41586-021-03994-2 via crossref
- doi:10.1073/pnas.2122940119 via crossref
- doi:10.1016/j.tig.2017.08.006 via crossref
- doi:10.1038/nbt.3128 via crossref
- doi:10.1038/nature21683 via crossref
- doi:10.1016/j.dib.2020.105895 via crossref
- doi:10.1038/s41580-023-00674-z via crossref
- doi:10.1667/rade-20-00013 via crossref
- doi:10.1111/imr.13042 via crossref
- doi:10.3390/ncrna7010015 via crossref
- doi:10.1038/nature21688 via crossref
- doi:10.1038/s41589-018-0021-8 via crossref
- doi:10.7554/elife.26693 via crossref
- doi:10.1038/s41467-020-18377-w via crossref
- doi:10.15252/embj.2022111179 via crossref
- doi:10.1101/gad.10.16.2067 via crossref
- doi:10.1016/j.molcel.2007.11.012 via crossref
- doi:10.1101/gad.973302 via crossref
- doi:10.1074/jbc.m114.573725 via crossref
- doi:10.1083/jcb.201611135 via crossref
- doi:10.1016/j.cell.2007.02.013 via crossref
- doi:10.1016/j.cell.2007.02.003 via crossref
- doi:10.1038/s12276-022-00902-0 via crossref
- doi:10.1038/nrd.2016.256 via crossref
- doi:10.1016/j.trecan.2017.08.004 via crossref
- doi:10.15252/embr.201541113 via crossref
- doi:10.3390/cancers14133270 via crossref
- doi:10.3389/fgene.2022.906662 via crossref
- doi:10.1038/s41418-023-01136-x via crossref
- doi:10.1038/nchembio.2087 via crossref
- doi:10.1016/j.chembiol.2017.02.006 via crossref
- doi:10.1038/nchembio.2085 via crossref
- doi:10.1038/s41388-018-0620-6 via crossref
- doi:10.1016/j.bmcl.2017.05.016 via crossref
- doi:10.1371/journal.pone.0271145 via crossref
- doi:10.1080/21505594.2022.2093444 via crossref
- doi:10.1016/j.celrep.2015.11.007 via crossref
- doi:10.1016/j.celrep.2013.12.021 via crossref
- doi:10.1101/gad.869501 via crossref
- doi:10.1038/nrd.2016.211 via crossref
- doi:10.1002/anie.201507978 via crossref
- doi:10.1038/s41467-020-19532-z via crossref
- doi:10.1158/1535-7163.mct-21-0841 via crossref
Source provenance
- crossref
- last seen: 2026-05-20T01:00:17.775839+00:00
- europepmc
- last seen: 2026-05-20T01:45:00.602351+00:00
- unpaywall
- last seen: 2026-05-26T02:00:01.498150+00:00
License: CC-BY-NC-ND-4.0